Drug Name,MOA,Experiments,Method,Measurement,Value,Unit
,Neuraminidase (Sialidase) (Influenza A Virus) Inhibitors,"Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO",,IC-50,2.10E-14,M
Methotrexate,Dihydrofolate Reductase (DHFR) (Protozoal) Inhibitors;Folate Antagonists;Dihydrofolate Reductase (DHFR) Inhibitors,"Dihydrofolate Reductase (DHFR) inhibition, IN VITRO",Dihydrofolic acid as substrate,Ki,3.40E-12,M
CGS-21680,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Hypertension remission/reduction, IN VITRO",,EC-50,1.00E-10,M
Danshensu Yibingzhi,Antioxidants,"Arteriosclerosis, coronary remission/reduction, IN VITRO",,MEC,1.00E-10,M
REGN-1001,Anti-ANGPTL4 (Angiopoietin-Related Protein 4),"Angiopoietin-Related Protein 4 affinity, IN VITRO",,Kd,1.00E-10,M
"1,25-Dihydroxyvitamin-D3",Signal Transduction Modulators;Vitamin D Receptor (VDR) Agonists,"Cytotoxicity induction, IN VITRO",Thymidine incorporation assay,IC-50,1.10E-10,M
Substance P,Tachykinin NK1 Receptor Ligands;Signal Transduction Modulators,Not Applicable,,IC-50,1.41E-10,M
Binodenoson,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Hypertension remission/reduction, IN VITRO",,EC-50,2.00E-10,M
Paricalcitol,Signal Transduction Modulators;Vitamin D Receptor (VDR) Agonists;Parathyroid Hormone Secretion Inhibitors,"Cytotoxicity induction, IN VITRO",Thymidine incorporation assay,IC-50,2.00E-10,M
Zotarolimus,Signal Transduction Modulators;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors,"Cytotoxicity remission/reduction, IN VITRO",Thymidine incorporation assay,IC-50,2.40E-10,M
PD-156707,"Signal Transduction Modulators;Endothelin-1 Receptor (EDNRA, ETAR) Antagonists","Endothelin-1 Receptor (ET-A) affinity, IN VITRO",Displacement of [125I]-endothelin-1,IC-50,4.30E-10,M
Adenosine,Adenosine Receptor Agonists;Signal Transduction Modulators,"Hypertension remission/reduction, IN VITRO",,EC-50,5.00E-10,M
Nisoldipine,Calcium Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,IC-50,5.00E-10,M
Mecasermin,Insulin Receptor Ligands;Signal Transduction Modulators,"Insulin Receptor affinity, IN VITRO",Displacement of [125I]-insulin-like growth factor-I,IC-50,6.90E-10,M
Barnidipine hydrochloride,Calcium Channel Blockers,"L-Type Calcium Channel (nonspecified subtype) affinity, IN VITRO",Displacement of [3H]-nitrendipine,IC-50,8.00E-10,M
Chloroquine,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,8.00E-10,M
Sodium nitroprusside,Nitric Oxide (NO) Donors;Guanylate Cyclase Activators,Not Applicable,,IC-50,8.05E-10,M
AZD-2716,Secretory Phospholipase A2 (sPLA2) Inhibitors;Signal Transduction Modulators,"Phospholipase A2, Group IA (secretory) inhibition, EX VIVO",,IC-50,1.00E-09,M
Doconexent,Signal Transduction Modulators;Pyroptosis Inducers;Free Fatty Acid Receptor 4 (FFAR4; GPR120) Agonists;PPARalpha Agonists,"Large Conductance BK(Ca) Potassium Channel (Maxi K+ Channel) (nonspecified subtype) activation, IN VITRO",Whole-cell patch-clamp assay (-40 mV),MEC,1.00E-09,M
N-acetylneuraminic acid ammonium,,"Cardiotoxicity protection, IN VITRO",Dye assay (WST-8),MIC,1.00E-09,M
Nafamostat mesilate,Tryptase Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Vero cells (TMPRSS2-expressing) transfected with MERS,IC-50,1.00E-09,M
CVS-1123,Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways,"Prothrombin (Thrombin) inhibition, IN VITRO",,IC-50,1.13E-09,M
Silvestrol,Eukaryotic Initiation Factor 4A (eIF4A) Inhibitors;Apoptosis Inducers,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Plaque assay,IC-50,1.30E-09,M
Ciclosporin,Cyclophilin D Inhibitors;Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;INS Expression Inhibitors,"Nuclear Factor of Activated T-cells (NFAT, nonspecified subtype) inhibition, IN VITRO",Luciferine/luciferase assay,IC-50,1.60E-09,M
Efonidipine hydrochloride ethanol,Calcium Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,IC-50,1.60E-09,M
LY-215840,5-HT2A Receptor Antagonists;Signal Transduction Modulators;5-HT7 Receptor Antagonists,"5-Hydroxytryptamine Receptor 2B (5-HT2B) affinity, IN VITRO",Displacement of [3H]-serotonin,Ki,1.89E-09,M
AZD-5718,Signal Transduction Modulators;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;Leukotriene Synthesis Inhibitors,"Arachidonate 5-Lipoxygenase-activating Protein (FLAP) inhibition, IN VITRO",ELISA assay,IC-50,2.00E-09,M
Efavirenz,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Infection, HIV remission/reduction, IN VITRO",Dye assay (MTT),IC-50,2.00E-09,M
RA-2,"Intermediate Conductance K(Ca) 3.1 (IKCa1; Gardos Channel, SK41, IK1) Channel Blockers;Small Conductance SK (Ca) 2.3 (SK3; SKCa3; hKCa3) Channel Blockers","Small Conductance Calcium-Activated Potassium Channel Protein 3 (SK3) blockade, IN VITRO",Whole-cell patch-clamp assay,IC-50,2.00E-09,M
Tricostatin A,CDKN1A Expression Enhancers;Apoptosis Inducers;Angiogenesis Inhibitors;ID1 Expression Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Epigenetic Modifier Modulators,"Histone Deacetylase (HDAC) (nonspecified subtype) inhibition, IN VITRO",Cell-free assay,IC-50,2.00E-09,M
SG-85,3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C Protease (Enterovirus 71) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors,"Infection, enterovirus remission/reduction, IN VITRO",Cytopathicity assay,IC-50,2.20E-09,M
Elgodipine hydrochloride,Calcium Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,IC-50,2.30E-09,M
Androstanolone,Androgen Receptor Agonists;Signal Transduction Modulators,"Vascular Cell Adhesion Protein 1 (VCAM-1) inhibition, IN VITRO",ELISA assay,MIC,2.50E-09,M
NECA,Signal Transduction Modulators;Adenosine Receptor Agonists,"Prostaglandin F2-alpha Receptor (PGF2-alpha Receptor) antagonism, IN VITRO",,IC-50,3.18E-09,M
Nifedipine,"P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Nuclear Factor of Activated T-Cells, Cytoplasmic 2 (NFAT1, NFATC2) Inhibitors;Antioxidants;Calcium Channel Blockers","Muscarinic Acetylcholine Receptor M3 antagonism, IN VITRO",,IC-50,3.20E-09,M
Fluvoxamine maleate,Signal Transduction Modulators;5-HT Reuptake Inhibitors,"Serotonin Transporter (SERT; 5-HTT) inhibition, IN VITRO",,IC-50,3.80E-09,M
E-4021,Signal Transduction Modulators;Phosphodiesterase PDE5A Inhibitors,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",,IC-50,3.90E-09,M
PF-835231,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescent assay,IC-50,4.00E-09,M
Sildenafil hydrochloride,Signal Transduction Modulators;Phosphodiesterase PDE5A Inhibitors,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,4.00E-09,M
Cerivastatin sodium,3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,"Cytotoxicity remission/reduction, IN VITRO",,IC-50,5.00E-09,M
Daunorubicin,DNA Topoisomerase II Inhibitors;DNA Topoisomerase I Inhibitors,"Leukemia, acute lymphocytic remission/reduction, IN VITRO",Dye assay (alamar blue),IC-50,5.00E-09,M
Dolutegravir sodium,HIV Integrase Inhibitors;Solute Carrier Family 22 Member 2 (SLC22A2; OCT2) Inhibitors,"HIV Integrase inhibition, IN VITRO",Strand transfer assay,IC-50,5.00E-09,M
Doxorubicin hydrochloride,DNA-Intercalating Drugs;DNA Topoisomerase II alpha Inhibitors,"Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO",Dye assay (sulforhodamine B),CC-50,5.00E-09,M
Ribavirin,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors,"Avian influenza remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.13E-09,M
Regadenoson,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Hypertension remission/reduction, IN VITRO",,EC-50,6.40E-09,M
VUF-8929,Calcium Channel Blockers,"L-Type Calcium Channel (nonspecified subtype) affinity, IN VITRO",,pKd,6.43E-09, 
Sch-58261,Signal Transduction Modulators;Adenosine A2A Receptor Antagonists,"Adenosine Receptor (nonspecified subtype) antagonism, IN VITRO",,IC-50,6.80E-09,M
Urocortin 2,CRF2 Receptor Agonists;Signal Transduction Modulators,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,7.50E-09,M
Indometacin,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;NADPH Oxidase (NOX) Inhibitors,"Cyclooxygenase-1 (COX-1) inhibition, IN VITRO",,IC-50,8.00E-09,M
Raltegravir potassium,HIV Integrase Inhibitors,"Infection, HIV remission/reduction, IN VITRO",Viral replication assay,IC-50,8.00E-09,M
Varespladib,Secretory Phospholipase A2 (sPLA2) Inhibitors;Signal Transduction Modulators,"Phospholipase A2, Group IA (secretory) inhibition, IN VITRO",Fluorescent assay,IC-50,8.00E-09,M
JTV-506,Potassium Channel Activators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,8.10E-09,M
Colchicine,Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs,"Leukemia, acute promyelocytic (M3) remission/reduction, IN VITRO",Dye assay (MTT),CC-50,8.60E-09,M
GW-8510,Signal Transduction Modulators;CDK2/Cyclin A Inhibitors,"CDK2/Cyclin A inhibition, IN VITRO",,IC-50,9.70E-09,M
Amphotericin B,,"Leishmaniasis remission/reduction, IN VITRO",Promastigote assay,IC-50,1.00E-08,M
BanLec,,"Cytotoxicity induction, IN VITRO",,CC-50,1.00E-08,M
Bortezomib,NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Proteasome Inhibitors;Caspase 3 Activators;Apoptosis Inducers,"Leukemia, acute lymphocytic remission/reduction, IN VITRO",Dye assay (alamar blue),IC-50,1.00E-08,M
CCG-1423,,"Cardiotoxicity induction, IN VITRO",Creatine kinase assay,MCC,1.00E-08,M
Diclofenac sodium,Drugs Acting on Acid-Sensing Ion Channels (ASIC);Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors,"Cyclooxygenase-1 (COX-1) inhibition, IN VITRO",,IC-50,1.00E-08,M
Nitroglycerin,Cyclophilin D Inhibitors;Signal Transduction Modulators;Atrial Natriuretic Peptide A (NPR1; Guanylate Cyclase A) Receptor Ligands,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,IC-50,1.00E-08,M
Remdesivir,Nucleobindin-1 (NUCB1) Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-50,1.00E-08,M
Testosterone,Androgen Receptor Agonists;Signal Transduction Modulators,Not Applicable,Dye assay (MTT),MEC,1.00E-08,M
Eniporide mesilate,Na+/H+ Exchanger type 1 (NHE-1) Inhibitors,"Sodium/Hydrogen Exchanger 1 (NHE-1) inhibition, IN VITRO",Sodium uptake assay,IC-50,1.04E-08,M
ZM-241385,Signal Transduction Modulators;Adenosine A2B Receptor Antagonists;Adenosine A2A Receptor Antagonists,"Adenosine A2A Receptor antagonism, IN VITRO",,IC-50,1.14E-08,M
PJ-34,Signal Transduction Modulators;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibitors,"N Protein affinity, IN VITRO",Surface plasmon resonance assay,Kd,1.17E-08,M
ARN-398,Acid Ceramidase (ACDase; ASAH1) Inhibitors,"Ceramidase (nonspecified) inhibition, IN VITRO",,IC-50,1.20E-08,M
Sinefungin,Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators,"RNA (Guanine-7-) Methyltransferase inhibition, IN VITRO",,IC-50,1.20E-08,M
SR9EK1,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-90,1.25E-08,M
HTCC,,"Infection, viral remission/reduction, IN VITRO",RNA assay,IC-50,1.34E-08,M
Lycorine,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Dye assay,IC-50,1.57E-08,M
Ergotamine,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,1.70E-08,M
IN-1130,Signal Transduction Modulators;Activin Receptor Like Kinase 4 (ALK4; ActR-IB) Inhibitors;TGF-beta Receptor Type-1 (TGFBR1; ALK5; SKR4; TbetaR-I) Inhibitors,"TGF-beta Receptor type-1 (TGFR-1; ALK5) inhibition, IN VITRO",Casein as substrate,IC-50,1.70E-08,M
Dihydroergotamine,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,2.00E-08,M
Glybenclamide,K(ATP) Channel Blockers;TRPA1 Agonists;K(ir) 6.2/SUR1 Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell voltage-clamp assay (0 mV),IC-50,2.00E-08,M
Rupintrivir,HRV 3C Protease Inhibitors,"Infection, rhinovirus remission/reduction, IN VITRO",Viral replication assay,IC-50,2.00E-08,M
Anandamide,TRPV1 (Vanilloid VR1 Receptor) Agonists;Signal Transduction Modulators;K(V) 4.3 Channel Blockers;Apoptosis Inducers;Cannabinoid CB1 Receptor Agonists,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,IC-50,2.23E-08,M
G-Strophanthin,Na+/K+-ATPase Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,IC-50,2.30E-08,M
Carmofur,Thymidylate Synthase Inhibitors;Pyrimidine Antagonists,"Ceramidase (nonspecified) inhibition, IN VITRO",,IC-50,2.90E-08,M
Aclarubicin,DNA Topoisomerase II Inhibitors,"Prostaglandin F2-alpha Receptor (PGF2-alpha Receptor) antagonism, IN VITRO",,IC-50,3.00E-08,M
C-90,Adenylate Cyclase Type 5 (ADCY5) Inhibitors,"Adenylate Cyclase (nonspecified subtype) inhibition, IN VITRO",cAMP accumulation assay,IC-50,3.00E-08,M
JMF-1507,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescent assay,Ki,3.00E-08,M
U-46619,,Not Applicable,,EC-50,3.00E-08,M
Pristimerine,3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,MIC,3.13E-08,M
DFU,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"Cyclooxygenase-2 (COX-2) inhibition, IN VITRO",,IC-50,4.00E-08,M
Emetine,Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors,"Leukemia, acute monocytic (M5b) remission/reduction, IN VITRO",Flow cytometry assay,CC-50,4.00E-08,M
GC-373,3C-Like Protease (Norovirus) Inhibitors,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,4.00E-08,M
Isoprenaline hydrochloride,Signal Transduction Modulators;beta-Adrenoceptor Agonists,"Prostaglandin F2-alpha Receptor (PGF2-alpha Receptor) antagonism, IN VITRO",,IC-50,4.20E-08,M
RPR-101511A,Signal Transduction Modulators;Tyrosine Kinase Inhibitors,"Platelet-Activating Factor Receptor (PAF-R) antagonism, IN VITRO",Boyden chamber assay,IC-50,4.92E-08,M
GC-376,3C-Like Protease (Norovirus) Inhibitors,"Infection, viral remission/reduction, IN VITRO",Fluorescence resonance energy transfer (FRET) assay,IC-50,5.00E-08,M
Simvastatin,Thioredoxin Reductase 1 (TXNRD1; TR1) Inhibitors;HDL-Cholesterol Increasing Agents;3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors;Liver Carboxylesterase 1 (CES1; PMPMEase) Inhibitors,"Fibulin 2 induction, IN VITRO",RNA assay,MEC,5.00E-08,M
Pyrazofurin,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Nephrotoxicity induction, IN VITRO",Cell viability assay,CC-50,5.20E-08,g/l
TG-0205221,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",,Ki,5.30E-08,M
(+)-JQ-1,"Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors;Bromodomain-Containing Protein 2 (Brd2) Inhibitors;HIV Latency-Reversing Agents;Apoptosis Inducers;Drugs Targeting Bromodomain and Extra-Terminal (BET) Proteins;Bromodomain-Containing Protein 3 (Brd3, RING3-Like protein) Inhibitors;Epigenetic Modifier Modulators","Bromodomain-Containing Protein 4 (Brd4) affinity, IN VITRO",Chemiluminescent assay,IC-50,5.40E-08,M
SB-505124,Signal Transduction Modulators;Activin Receptor Like Kinase 4 (ALK4; ActR-IB) Inhibitors;Activin Receptor Like Kinase 7 (ALK7) Inhibitors;TGF-beta Receptor Type-1 (TGFBR1; ALK5; SKR4; TbetaR-I) Inhibitors,"TGF-beta Receptor type-1 (TGFR-1; ALK5) inhibition, IN VITRO",Casein as substrate,IC-50,5.40E-08,M
TKI-963,Signal Transduction Modulators;PDGFR Family Inhibitors;Angiogenesis Inhibitors,"Platelet-Derived Growth Factor Receptor beta (PDGFR-beta) inhibition, IN VITRO",Cell-free assay,Ki,5.60E-08,M
CVT-3033,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Hypertension remission/reduction, IN VITRO",,EC-50,6.79E-08,M
Levcromakalim,K(ATP) Channel Activators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,6.90E-08,M
5-Hydroxytriptamine,Signal Transduction Modulators;5-HT2C Receptor Ligands,Not Applicable,,EC-50,7.33E-08,M
Insulin glargine,Signal Transduction Modulators;Insulin Receptor Agonists,"Insulin Receptor affinity, IN VITRO",Displacement of [125I]-insulin-like growth factor-I,IC-50,7.50E-08,M
Amesergide,5-HT2A Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 7 (5-HT7) affinity, IN VITRO",Displacement of [3H]-serotonin,Ki,7.80E-08,M
Apicidin,Histone Deacetylase (HDAC) Inhibitors;Epigenetic Modifier Modulators,"Leukemia, B-cell acute lymphocytic remission/reduction, IN VITRO",Dye assay (alamar blue),IC-50,8.00E-08,M
Pravastatin sodium,3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,8.10E-08,M
CDP,,"P2Y Purinoceptor 2 (P2Y2) agonism, IN VITRO",Fluorescent assay,EC-50,8.71E-08,M
Avitriptan,5-HT1D Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,8.90E-08,M
"6',6'-Difluoroaristeromycin",S-Adenosyl-L-Homocysteine Hydrolase Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Plaque assay,MIC,1.00E-07,M
Azithromycin,Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,1.00E-07,M
beta-Thujaplicinol,Protein P (Ribonuclease H; RNHase) (Hepatitis B Virus) Inhibitors;2''-Aminoglycoside Nucleotidyltransferase (Escherichia coli) Inhibitors;HIV Integrase Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,1.00E-07,M
Human angiotensin II,Signal Transduction Modulators;Type-1 Angiotensin II Receptor (AGTR1; AT1) Ligands;Type-2 Angiotensin II Receptor (AGTR2; AT2) Ligands,"Acute coronary syndrome induction, IN VIVO",,MED,1.00E-07,g/kg/min
IIS,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,1.00E-07,M
Isobavachalcone,Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants,"Tumor Necrosis Factor (TNF-alpha) inhibition, IN VITRO",Chemiluminescent assay,MIC,1.00E-07,M
Luteolin,MAO-A Inhibitors;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Antiinflammatory Drugs;Xanthine Oxidase Inhibitors;Antioxidants;Apoptosis Inducers;Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Inhibitors;Aldose Reductase Inhibitors;Nitric Oxide (NO) Production Inhibitors,"Fibrillation, ventricular remission/reduction, IN VIVO",Artery (coronary) ligation,MED,1.00E-07,g/kg
Mesulergine hydrochloride,Dopamine Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,1.00E-07,M
Niclosamide,Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.00E-07,M
Nocodazole,Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",Dye assay (sulforhodamine B),CC-50,1.00E-07,M
Promazine,Signal Transduction Modulators;Dopamine Receptor Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,MIC,1.00E-07,M
Tingenone,3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers,"Cytotoxicity induction, IN VITRO",Dye assay (alamar blue),CC-50,1.00E-07,M
Zaprinast,Signal Transduction Modulators;Insulin Sensitizers;Phosphodiesterase PDE5A Inhibitors,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-07,M
Sergolexole,5-HT2A Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 7 (5-HT7) affinity, IN VITRO",Displacement of [3H]-serotonin,Ki,1.01E-07,M
Mevastatin,3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,1.07E-07,M
SR9EK2,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-90,1.08E-07,M
IIQ,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,1.10E-07,M
Lovastatin,3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,1.24E-07,M
VH-298,Von Hippel-Lindau Disease Tumor Suppressor (VHL) Inhibitors,"von Hippel-Lindau Disease Tumor Suppressor (VHL) affinity, IN VITRO",Chemiluminescent assay,IC-50,1.27E-07,M
Isosorbide dinitrate,,"Prostaglandin F2-alpha Receptor (PGF2-alpha Receptor) antagonism, IN VITRO",,IC-50,1.30E-07,M
Cerebrocrast,Calcium Channel Blockers,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,1.37E-07,M
Vinblastine sulfate,Antimitotic Drugs;Microtubule Destabilizers (Tubulin Polymerization Inhibitors),"Tubulin inhibition, IN VITRO",Spectrophotometric assay,IC-50,1.50E-07,M
Amlodipine besylate,Calcium Channel Blockers,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,1.64E-07,M
Mycophenolic acid sodium salt,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.70E-07,M
Naratriptan hydrochloride,5-HT1D Receptor Agonists;5-HT1B Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,1.71E-07,M
JMF-1521,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.80E-07,M
Cycloheximide,Signal Transduction Modulators;Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Ferroptosis Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.90E-07,M
Hedyforrestin C,Signal Transduction Modulators;IL-12 Production Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,IC-50,1.90E-07,M
Quinacrine hydrochloride,Secretory Phospholipase A2 (sPLA2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Cytokine Production Inhibitors;TP53 Expression Enhancers,"Cytotoxicity induction, IN VITRO",Propidium iodide assay,MEC,2.00E-07,M
Dotarizine,Signal Transduction Modulators;Calcium Channel Blockers;5-HT2 Receptor Antagonists,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,2.20E-07,M
Mycophenolate mofetil,Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,2.30E-07,M
N-3,3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",MCA-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-lys(Dnp)-lys-NH2 as substrate,Ki,2.30E-07,M
Methysergide,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,2.43E-07,M
Betulinic acid,Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors,"GABA(A) BZ Site Receptor affinity, IN VITRO",Displacement of [3H]-flunitrazepam,Ki,2.60E-07,M
P-21S8,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,2.60E-07,M
Podofilox,Potassium Channel Subfamily K Member 18 (TRESK; KCNK18) Blockers;Antimitotic Drugs,"Tubulin inhibition, IN VITRO",Spectrophotometric assay,IC-50,2.60E-07,M
SKA-31,"Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1; Gardos Channel, SK41, IK1) Channel Activators","Intermediate Conductance K(Ca) 3.1 (IKCa1; SK4, KCa3.1) Channels activation, IN VITRO",,EC-50,2.60E-07,M
BTB-06256,,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescent assay,IC-50,3.00E-07,M
Chloroquine phosphate,Apoptosis Inducers,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,3.06E-07,M
HM-HTCC,,"Infection, viral remission/reduction, IN VITRO",RNA assay,IC-50,3.09E-07,M
Levosimendan,K(ATP) Channel Activators;Calcium Sensitizers;Nitric Oxide (NO) Production Inhibitors,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,IC-50,3.10E-07,M
GRL-0667,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,3.20E-07,M
Oseltamivir,,"Avian influenza remission/reduction, IN VITRO",Cytopathicity assay,IC-50,3.30E-07,M
P-21S10,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,3.30E-07,M
KIN-269,Interferon Regulatory Factor 3 (IRF-3) Activators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.90E-07,M
Meloxicam,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors,"Cyclooxygenase-1 (COX-1) inhibition, IN VITRO",,IC-50,4.00E-07,M
Atorvastatin calcium,Signal Transduction Modulators;Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;TNFSF6 Expression Inhibitors;3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,4.17E-07,M
Nicorandil,K(ATP) Channel Activators;Nitric Oxide (NO) Donors,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,4.20E-07,M
MZ-1,Anti-Periostin,"Bromodomain-Containing Protein 4 (Brd4) affinity, IN VITRO",Chemiluminescent assay,IC-50,4.32E-07,M
Gemcitabine hydrochloride,Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,4.40E-07,M
Rizatriptan,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,4.48E-07,M
M-232,Histone Deacetylase (HDAC) Inhibitors;Epigenetic Modifier Modulators,"Histone Deacetylase (HDAC) (nonspecified subtype) inhibition, IN VITRO",Cell-free assay,IC-50,4.60E-07,M
Baicalein,Drugs Targeting on Quorum Sensing Signaling;Signal Transduction Modulators;AR Expression Inhibitors;15-Lipoxygenase Inhibitors;Autophagy Inducers;12-Lipoxygenase Inhibitors;Dual Specificity Protein Phosphatase 3 (VHR) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Apoptosis Inducers;Protein Tyrosine Phosphatase (PTP) Inhibitors,"ATP-Dependent DNA Helicases inhibition, IN VITRO",Fluorescence resonance energy transfer (FRET) assay,IC-50,4.70E-07,M
H-89,Voltage-Gated K(V) Channel Blockers;Signal Transduction Modulators;cAMP-Dependent Protein Kinase (PKA) Inhibitors;RAC Serine/Threonine-Protein Kinase (AKT; PKB) Inhibitors,"Large Conductance BK(Ca) Potassium Channel (Maxi K+ Channel) (nonspecified subtype) activation, IN VITRO",,EC-50,4.70E-07,M
Zolmitriptan,5-HT1D Receptor Agonists;5-HT1B Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,4.76E-07,M
Eribis peptide-94,Signal Transduction Modulators;Drugs Acting on Opioid and Opioid-Like Receptors;Nitric Oxide Synthase Activators,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,5.00E-07,g/kg
Ferruginol,3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers,"Catenin beta-1 activation, IN VITRO",Chemiluminescent assay,MEC,5.00E-07,M
MAC-5576,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",,IC-50,5.00E-07,M
RMNC-6,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",,IC-50,5.00E-07,M
Sunitinib malate,Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret (RET; CDHF12; PTC) Inhibitors;VEGFR-3 (FLT4) Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;FLT3 (FLK2/STK1) Inhibitors;Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R; CD115; c-Fms) Inhibitors;KIT (C-KIT) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2; Dardarin) Inhibitors;VEGFR-2 (FLK1; KDR) Inhibitors;Angiogenesis Inhibitors;VEGFR-1 (FLT1) Inhibitors,"Leukemia, acute lymphocytic remission/reduction, IN VITRO",Dye assay (alamar blue),IC-50,5.00E-07,M
UTP,Signal Transduction Modulators;P2Y2 Receptor Agonists,"P2Y Purinoceptor 2 (P2Y2) agonism, IN VITRO",Fluorescent assay,EC-50,5.30E-07,M
Thalidomide,Signal Transduction Modulators;Protein Cereblon (CRBN) Inhibitors;TNF-alpha Production Inhibitors;Angiogenesis Inhibitors,"Cereblon affinity, IN VITRO",Chemiluminescent assay,IC-50,5.40E-07,M
ABT-737,Signal Transduction Modulators;Bcl-2-Like Protein 2 (Bcl-W; BCL2L2) Inhibitors;Apoptosis Inducers;Apoptosis Regulator Bcl-2 Inhibitors;Bcl-2-Like Protein 1 (Bcl-xl; Bcl-X; BCL2L1) Inhibitors,"Leukemia, B-cell acute lymphocytic remission/reduction, IN VITRO",Dye assay (alamar blue),IC-50,5.50E-07,M
GRL-0617,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,5.60E-07,M
Diltiazem hydrochloride,L-Type Calcium Channel Blockers,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,5.98E-07,M
Coronaridine,Transient Receptor Potential Cation Channel Subfamily M Member 8 (TRPM8) Antagonists;Acetylcholinesterase (AChE) Inhibitors;Wnt Signaling Inhibitors,"Transient Receptor Potential Cation Channel subfamily M member 8 (TRPM8) blockade, IN VITRO",Fluorescent assay,IC-50,6.00E-07,M
HR2P,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.00E-07,M
YT-146,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Adenosine A2A Receptor affinity, IN VITRO",Displacement of [3H]-ZM-241385,Ki,6.09E-07,M
AMP-579,Signal Transduction Modulators;Adenosine A2A Receptor Agonists;Adenosine A1 Receptor Agonists,"Inflammatory disorders remission/reduction, IN VITRO",,IC-50,6.10E-07,M
Eptifibatide,Signal Transduction Modulators;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways,"Thrombotic Disorders remission/reduction, IN VITRO",Turbidimetric assay,IC-50,6.27E-07,M
Betulonic acid,Lysosomal alpha-Glucosidase (GAA) Inhibitors;E3 Ubiquitin-Protein Ligase Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.30E-07,M
HR2P-M2,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,6.40E-07,M
Tanshinone I,Signal Transduction Modulators;AP-1 Transcription Factor Complex Inhibitors;Aryl Hydrocarbon Receptor (AhR) Ligands,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Ubiquitin-7-amino-4-methylcoumarin as substrate,IC-50,7.00E-07,M
dBET-1,"Bromodomain-Containing Protein 4 (Brd4, HUNK1) Degradation Inducers;Apoptosis Inducers;Drugs Targeting Protein Cereblon (CRBN);Epigenetic Modifier Modulators","Bromodomain-Containing Protein 4 (Brd4) affinity, IN VITRO",Chemiluminescent assay,IC-50,7.47E-07,M
Phenazopyridine hydrochloride,,"Hepatitis, viral remission/reduction, IN VITRO",Viral replication assay,IC-50,7.70E-07,M
[N-MeIle4]-cyclosporin,Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,8.00E-07,M
Alisporivir,P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,8.00E-07,M
Clamikalant,K(ATP) Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell voltage-clamp assay (0 mV),IC-50,8.00E-07,M
Iguesterin,3C-Like Protease (SARS-CoV) Inhibitors,"Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO",Fluorescent assay,Ki,8.00E-07,M
Sumatriptan,5-HT1D Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,8.03E-07,M
Zaldaride maleate,Calmodulin Antagonists,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-60 mV),IC-50,8.10E-07,M
Y-27632,Signal Transduction Modulators;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2; Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1; p160-ROCK) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-60 mV),IC-50,8.70E-07,M
Geldanamycin,Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",,IC-50,9.10E-07,M
Bradykinin,Signal Transduction Modulators;Bradykinin B2 Receptor Agonists,"Muscarinic Acetylcholine Receptor M2 antagonism, IN VITRO",,MIC,1.00E-06,M
Esmolol hydrochloride,beta1-Adrenoceptor Antagonists;Signal Transduction Modulators,"Hypertension remission/reduction, IN VITRO",,MEC,1.00E-06,M
Imatinib mesylate,Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Tyrosine-Protein Kinase ABL1 (ABL) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R; CD115; c-Fms) Inhibitors;KIT (C-KIT) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors,"Platelet-Derived Growth Factor (PDGF) (nonspecified subtype) antagonism, IN VITRO",,MIC,1.00E-06,M
Mibefradil,Sodium Channel Protein Type 2 Subunit alpha (Nav1.2) Channel Blockers;Sodium Channel Protein Type 9 Subunit alpha (Nav1.7) Channel Blockers;T-Type Calcium Channel Blockers;Sodium Channel Protein Type 4 Subunit alpha (Nav1.4) Channel Blockers;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers,"L-Type Calcium Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-80 mV),IC-50,1.00E-06,M
Psoralidin,Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers,"5-Hydroxytryptamine Receptor 1A (5-HT1A) agonism, IN VITRO",Chemiluminescent assay,MEC,1.00E-06,M
Quercetin,Catechol-O-Methyl Transferase (COMT) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Signal Transduction Modulators;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Xanthine Oxidase Inhibitors;EGFR (HER1; erbB1) Inhibitors;Cytokine Production Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Aldose Reductase Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Free Radical Scavengers;Epigenetic Modifier Modulators;Wnt Signaling Inhibitors,"Fatty acid oxidation disorders remission/reduction, IN VITRO",TBARS formation assay,MIC,1.00E-06,M
Vitamin E,Antioxidants,"Fatty acid oxidation disorders remission/reduction, IN VITRO",TBARS formation assay,MIC,1.00E-06,M
Mibefradil hydrochloride,T-Type Calcium Channel Blockers;L-Type Calcium Channel Blockers,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (+20 mV),Ki,1.01E-06,M
Mucroporin-M1,Cell Membrane Disrupting Agents,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,1.03E-06,M
18-Methoxycoronaridine,Signal Transduction Modulators;Nicotinic alpha3beta4 Receptor Antagonists,"Nicotinic alpha3beta4 Receptor antagonism, IN VITRO",Fluorescent assay,IC-50,1.06E-06,M
2'-C-Methylguanosine,RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.10E-06,M
Ascochlorin,Signal Transduction Modulators;AP-1 Transcription Factor Complex Inhibitors,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",,IC-50,1.10E-06,M
Vidarabine,Adenylate Cyclase Type 6 (ADCY6) Inhibitors;Adenylate Cyclase Type 5 (ADCY5) Inhibitors,"Adenylate Cyclase (nonspecified subtype) inhibition, IN VITRO",cAMP accumulation assay,IC-50,1.11E-06,M
Chlorpyrifos,,"Hepatitis, viral remission/reduction, IN VITRO",Viral replication assay,IC-50,1.12E-06,M
DTPMPA,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"ATPase (nonspecified subtype) inhibition, IN VITRO",Phosphate release assay,IC-50,1.19E-06,M
6-Azauridine,,"Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO",Plaque assay,IC-50,1.20E-06,M
Ferulic acid ethyl ester,Antioxidants,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",Dye assay (sulforhodamine B),IC-50,1.20E-06,M
Ilicicolin F,,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",,IC-50,1.20E-06,M
Cisplatin,DNA Alkylating Drugs;Signal Transduction Modulators;Thioredoxin (TXN; TRX; TRDX) Inhibitors;TNFSF6 Expression Inhibitors;Apoptosis Inducers;BIRC4 Expression Enhancers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors,"Cancer, ovary (adenocarcinoma) remission/reduction, IN VITRO",Dye assay,CC-50,1.40E-06,M
Nifurtimox,,"Trypanosomiasis remission/reduction, IN VITRO",Amastigote (intracellular) assay,IC-50,1.40E-06,M
Aloxistatin,Calpain Inhibitors;Cathepsin B Inhibitors;Falcipain 2 Inhibitors;Cathepsin L Inhibitors;Antiamyloidogenic Agents,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.45E-06,M
RDS-1712,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"HIV Integrase inhibition, IN VITRO",Strand transfer assay,IC-50,1.47E-06,M
Ciprofloxacin hydrochloride,Melanin Ligands;DNA Gyrase (Bacterial) Inhibitors;DNA Topoisomerase IV (Bacterial) Inhibitors,"Tuberculosis remission/reduction, IN VITRO",Resazurin reduction assay,MIC,1.50E-06,M
ML-188,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",,IC-50,1.50E-06,M
Mycophenolic acid,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Infection, viral remission/reduction, IN VITRO",Plaque assay,IC-50,1.50E-06,M
UDP,,"P2Y Purinoceptor 2 (P2Y2) agonism, IN VITRO",Fluorescent assay,EC-50,1.50E-06,M
Trifluoperazine hydrochloride,Calcium/Calmodulin-Dependent Protein Kinase Type II (CAMK2) Inhibitors;Sodium Channel Protein Type 9 Subunit alpha (Nav1.7) Channel Blockers;Signal Transduction Modulators;Dopamine D2 Receptor (DRD2) Antagonists;Sodium Channel Protein Type 4 Subunit alpha (Nav1.4) Channel Blockers,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (+60 mV),IC-50,1.58E-06,M
OSI-9719,,Not Applicable,,EC-50,1.60E-06,M
Ferulaldehyde,Heat Shock Factor Protein 1 (HSF1) Activators;Nitric Oxide (NO) Production Inhibitors,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",Dye assay (sulforhodamine B),IC-50,1.70E-06,M
Flunarizine hydrochloride,Calcium Channel Blockers,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,1.70E-06,M
SCA-40,Signal Transduction Modulators;Phosphodiesterase PDE4 Inhibitors;Potassium Channel Activators;Phosphodiesterase PDE3 Inhibitors,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,IC-50,1.80E-06,M
15-Deoxy-prostaglandin J2,Farnesoid X Receptor (FXR) Antagonists;Signal Transduction Modulators;PPARgamma Agonists,"Cytotoxicity induction, IN VITRO",Dye assay,IC-50,2.00E-06,M
Coronarin D,Signal Transduction Modulators;NF-kappaB (NFKB) Activators;Apoptosis Inducers,"Caspase-3 activation, IN VITRO",Chemiluminescent assay,MEC,2.00E-06,M
RDS-1759,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Infection, HIV remission/reduction, IN VITRO",Viral replication assay,IC-50,2.10E-06,M
Amitriptyline hydrochloride,Signal Transduction Modulators;Norepinephrine Reuptake Inhibitors;5-HT Reuptake Inhibitors;Sodium Channel Protein Type 4 Subunit alpha (Nav1.4) Channel Blockers,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-60 mV),IC-50,2.20E-06,M
Bananin,Chelating Agents,"ATPase (nonspecified subtype) inhibition, IN VITRO",,IC-50,2.30E-06,M
Kaempferol 3-O-alpha-L-arabinofuranoside,Hedgehog Signaling Inhibitors;Antioxidants,"Hypothetical Protein Sars3a inhibition, IN VITRO",Voltage-clamp assay (-60 mV),IC-50,2.30E-06,M
Dieckol,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;beta-Secretase 1 (BACE1) Inhibitors;Acetylcholinesterase (AChE) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescence resonance energy transfer (FRET) assay,Ki,2.40E-06,M
CA-074Me,Cathepsin B Inhibitors;Antiamyloidogenic Agents,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,2.50E-06,M
EMAC-2076,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,2.50E-06,M
EMAC-2077,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,2.60E-06,M
Adenosine triphosphate,P2X Receptor Agonists;Signal Transduction Modulators,"P2Y Purinoceptor 2 (P2Y2) agonism, IN VITRO",Fluorescent assay,EC-50,2.70E-06,M
EMAC-2078,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,2.80E-06,M
Fasudil hydrochloride,Signal Transduction Modulators;Calcium Sensitizers;Rho Kinase Inhibitors,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,2.94E-06,M
Aceclofenac,,"Cyclooxygenase-2 (COX-2) inhibition, IN VITRO",,IC-50,3.00E-06,M
Aciclovir,DNA Polymerase Inhibitors,"Infection, herpes simplex virus remission/reduction, IN VITRO",Plaque assay,IC-50,3.00E-06,M
W-7,Calmodulin Antagonists;Potassium Voltage-Gated Channel Subfamily H Member 2 (KCNH2; hERG1; Kv11.1) Blockers;K(V) 1.5 (KCNA5) Channel Blockers,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-60 mV),IC-50,3.38E-06,M
SB-203580,Signal Transduction Modulators;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators;MAPK p38 Inhibitors;Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,IC-50,3.50E-06,M
Fluorouracil,Pyrimidine Antagonists;Apoptosis Inducers;Antimitotic Drugs;Dihydropyrimidine Dehydrogenase Inhibitors,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",,IC-50,3.60E-06,M
Amiodarone hydrochloride,Signal Transduction Modulators;Voltage-Gated Sodium Channel Blockers;Muscarinic M3 Receptor Ligands;Drugs Acting on Hyperpolarization-activated Cyclic Nucleotide-Gated (HCN) Channels,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-60 mV),IC-50,3.90E-06,M
NSC-727447,,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,4.00E-06,M
ML-300,3C-Like Protease (SARS-CoV) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",,IC-50,4.11E-06,M
Tripterin,Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors;Lipid Peroxidation Inhibitors;Cytokine Production Inhibitors;Apoptosis Inducers;Enoyl-(Acyl Carrier Protein) Reductase (FabI) (Plasmodium falciparum) Inhibitors;Antioxidants;Myc Proto-Oncogene Protein (c-Myc)/Myc-Associated Factor X (Max) Interaction Inhibitors,"Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO",Fluorescent assay,Ki,4.20E-06,M
Idarubicin hydrochloride,,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,4.21E-06,M
Eletriptan,5-HT1B Receptor Agonists;5-HT1D Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,EC-50,4.30E-06,M
K-131,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Poly(dC)-poly(rG) as template primer,IC-50,4.50E-06,M
trans-Resveratrol,NF-kappaB (NFKB) Modulators;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Extracellular-Regulated Kinase (ERK) Activators;MAO-A Inhibitors;Signal Transduction Modulators;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Lipid Peroxidation Inhibitors;Thioredoxin (TXN; TRX; TRDX) Inhibitors;Xanthine Oxidase Inhibitors;APOA1 Expression Enhancers;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Apoptosis Inducers;beta-Secretase 1 (BACE1) Inhibitors;Angiogenesis Inhibitors;DNA Topoisomerase II Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Epigenetic Modifier Modulators,"Histamine H1 Receptor antagonism, IN VITRO",,IC-50,4.50E-06,M
Xanthoangelol B,3C-Like Protease (SARS-CoV) Inhibitors;Cysteine Protease Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants;Sensor Histidine Kinase (Bacterial) Inhibitors;Plasminogen Activator Inhibitor (PAI-1) Inhibitors;Nitric Oxide (NO) Production Inhibitors;Free Radical Scavengers,"Anemia, hemolytic remission/reduction, IN VITRO",,IC-50,4.62E-06,M
Coronarin C,,"Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO",Dye assay (sulforhodamine B),IC-50,4.80E-06,M
Cinanserin hydrochloride,Serotonin Receptor Antagonists;Signal Transduction Modulators,"3C-Like Protease (viral) inhibition, IN VITRO",,IC-50,5.00E-06,M
K-123,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Poly(dC)-poly(rG) as template primer,IC-50,5.00E-06,M
Parstatin,Angiogenesis Inhibitors,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,5.00E-06,g/kg
Zacopride,Signal Transduction Modulators;5-HT3 Receptor Antagonists,"Arrhythmia, ventricular remission/reduction, IN VIVO",Artery (coronary) ligation,MED,5.00E-06,g/kg
AG-690/36550050,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,5.10E-06,M
SSYA-10-001,,"NTPase inhibition, IN VITRO",DNA as substrate,IC-50,5.30E-06,M
Ursolic acid,11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;HIV Protease Inhibitors;Lipid Peroxidation Inhibitors;Antiinflammatory Drugs;Caspase 3 Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Acetylcholinesterase (AChE) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,5.50E-06,M
Hedycoronen A,Signal Transduction Modulators;IL-6 Production Inhibitors;IL-12 Production Inhibitors;TNF-alpha Production Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,IC-50,5.60E-06,M
Flecainide acetate,Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Patch-clamp assay (-60 mV),IC-50,5.90E-06,M
Desipramine hydrochloride,Signal Transduction Modulators;Voltage-Gated Sodium Channel Blockers;Norepinephrine Transporter (NET) Inhibitors,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay,IC-50,5.91E-06,M
Isoimperatorin,Cytochrome P450 CYP1B1 Inhibitors,"Avian influenza remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.72E-06,M
Cisapride hydrate,5-HT4 Receptor Agonists;Signal Transduction Modulators,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Patch-clamp assay (-60 mV),IC-50,6.77E-06,M
Imperatorin,Voltage-Gated Sodium Channel Blockers;Apoptosis Inducers;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.93E-06,M
Oleanolic acid,Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;LDL Antioxidants;G-Protein Coupled Bile Acid Receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) Agonists;Antioxidants;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,7.50E-06,M
Eckol,Lipid Peroxidation Inhibitors;Tyrosinase Inhibitors;Free Radical Scavengers,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescence resonance energy transfer (FRET) assay,Ki,8.20E-06,M
Amentoflavone,Fatty Acid Synthase (FAS) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;Neutrophil Elastase (Leukocyte Elastase) Release Inhibitors;Xanthine Oxidase Inhibitors;Apoptosis Inducers;Antioxidants;Angiogenesis Inhibitors;beta-Hexosaminidase Release Inhibitors;GABA(A) Receptor Modulators;Cytosolic Phospholipase A2 (PLA2G4A; cPLA2) Inhibitors,"Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO",Fluorescent assay,IC-50,8.30E-06,M
Hesperetin,Transient Receptor Potential Cation Channel Subfamily M Member 3 (TRPM3) Antagonists;Lipid Lowering Agents;Antioxidants;Cytochrome P450 CYP1B1 Inhibitors;Triglyceride Lowering Agents,"3C-Like Protease (viral) inhibition, IN VITRO",Luciferine/luciferase assay,IC-50,8.30E-06,M
"1,5-Dicaffeoylquinic acid",HIV Integrase Inhibitors;Antioxidants;Nitric Oxide (NO) Production Inhibitors,"Ebola virus disease remission/reduction, IN VITRO",,IC-50,8.50E-06,M
Clomipramine hydrochloride,Signal Transduction Modulators;Serotonin Transporter (SERT) Inhibitors,"Voltage-Gated K(v) Channel (nonspecified subtype) blockade, IN VITRO",Patch-clamp assay (-80 mV),IC-50,8.61E-06,M
Insulin argine,,"Insulin Receptor affinity, IN VITRO",Displacement of [125I]-insulin-like growth factor-I,IC-50,8.70E-06,M
RDS-1643,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,9.20E-06,M
Pomolic acid,Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,9.30E-06,M
ZINC-20759448,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"HIV Reverse Transcriptase inhibition, IN VITRO",Poly(rA)-oligo(dT) as template primer,IC-50,9.75E-06,M
Bindarit,NF-kappaB (NFKB) Modulators;Signal Transduction Modulators,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),MIC,1.00E-05,M
Celecoxib,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;Apoptosis Inducers;Angiogenesis Inhibitors;Carbonic Anhydrase Inhibitors,"cAMP-Specific 3',5'-cyclic Phosphodiesterase 4 (PDE4) (nonspecified subtype) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-05,M
Landiolol hydrochloride,beta1-Adrenoceptor Antagonists;Signal Transduction Modulators,"Bradycardia induction, IN VITRO",,MEC,1.00E-05,M
Lixisenatide,Insulin Secretagogues;Signal Transduction Modulators;GLP-1 Receptor Agonists,"Myocardial infarction protection, IN VIVO",Artery (coronary) ligation,MED,1.00E-05,g/kg
Neuregulin-1,,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,1.00E-05,g/kg/h
Propofol,TRPV1 (Vanilloid VR1 Receptor) Agonists,Not Applicable,,MIC,1.00E-05,M
R9F2-PP-PMO,,"Hepatitis protection, IN VITRO",Gene reporter assay,IC-50,1.00E-05,M
Telmisartan,Type-1 Angiotensin II Receptor (AGTR1; AT1) Antagonists;PPARalpha Partial Agonists;Signal Transduction Modulators;PPARgamma Modulators,"Succinate Dehydrogenase Complex inhibition, IN VITRO",Spectrophotometric assay,MIC,1.00E-05,M
Phlorofucofuroeckol,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Antioxidants;beta-Secretase 1 (BACE1) Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescence resonance energy transfer (FRET) assay,Ki,1.06E-05,M
Voacangine,Transient Receptor Potential Cation Channel Subfamily M Member 8 (TRPM8) Antagonists;Acetylcholinesterase (AChE) Inhibitors,"Catenin beta-1 inhibition, IN VITRO",Luciferine/luciferase assay,IC-50,1.15E-05,M
Oxybutynin chloride,Muscarinic Receptor Antagonists;Signal Transduction Modulators,"Potassium Channels (nonspecified subtype) blockade, IN VITRO",Whole-cell patch-clamp assay (-80 mV),IC-50,1.15E-05,M
Milrinone,Signal Transduction Modulators;Phosphodiesterase PDE3 Inhibitors,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,IC-50,1.20E-05,M
rLj-RGD3,Apoptosis Inducers,"Myocardial infarction protection, IN VIVO",Dye extravasation assay,MED,1.20E-05,g/kg
Troglitazone,EGR1 Expression Enhancers;Signal Transduction Modulators;Insulin Sensitizers;PPARgamma Agonists;CCL2 Expression Inhibitors,"Cytotoxicity induction, IN VITRO",Dye assay,IC-50,1.30E-05,M
Sibrafiban,Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators;Inhibitors of Blood Coagulation Pathways,"Thrombotic Disorders remission/reduction, IN VITRO",,IC-50,1.50E-05,g/l
EICAR,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Antimetabolites,"Nephrotoxicity induction, IN VITRO",Dye assay,CC-50,1.60E-05,M
Teicoplanin,,"Infection, HIV remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.80E-05,M
Cidofovir,DNA Polymerase Inhibitors,"Infection, viral remission/reduction, IN VITRO",Plaque assay,IC-50,1.90E-05,M
Tranilast,"IL-10 Production Enhancers;Urate Transporter 1 (URAT1) Inhibitors;Signal Transduction Modulators;Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Activators;TNF-alpha Production Inhibitors;IFN-gamma Production Inhibitors;TRPV2 (Vanilloid VR2 Receptor) Antagonists;IL-2 Production Inhibitors;IL-4 Modulators","Cytotoxicity induction, IN VITRO",Thymidine incorporation assay,IC-50,1.90E-05,M
Digitoflavone,MAO-A Inhibitors;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Antiinflammatory Drugs;Xanthine Oxidase Inhibitors;Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Inhibitors;Antioxidants;Apoptosis Inducers;Aldose Reductase Inhibitors;Nitric Oxide (NO) Production Inhibitors,"Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO",Fluorescent assay,IC-50,2.00E-05,M
Pimagedine,Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Signal Transduction Modulators;AGE Inhibitors (Maillard's Reaction Inhibitors),"Inflammatory disorders remission/reduction, IN VITRO",,IC-50,2.14E-05,M
Ethynylcytidine,Apoptosis Inducers;DNA-Directed RNA Polymerase Inhibitors,"Infection, poliovirus remission/reduction, IN VITRO",Plaque assay,IC-50,2.30E-05,M
Lamivudine,DNA Polymerase Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,2.73E-05,M
ADP,,"P2Y Purinoceptor 2 (P2Y2) agonism, IN VITRO",Fluorescent assay,EC-50,2.93E-05,M
Idarubicinol,,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,IC-50,3.07E-05,M
Edetic acid,Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors,"Hyperferritinemia remission/reduction, IN VITRO",Spectrophotometric assay,EC-50,4.20E-05,M
Adefovir dipivoxil,DNA Polymerase Inhibitors,"Hepatitis B (HBV) remission/reduction, IN VITRO",ELISA assay,MIC,5.00E-05,M
Cocaine,Dopamine Reuptake Inhibitors;Signal Transduction Modulators,"Apoptosis induction, IN VITRO",Dye assay,EC-50,5.00E-05,M
N-Desethylamiodarone,Apoptosis Inducers,"Arrhythmia, ventricular remission/reduction, IN VIVO",Artery (coronary) ligation,MED,5.00E-05,g/kg
PF-02378867,,"3C-Like Protease (viral) inhibition, IN VITRO",Fluorescent assay,IC-50,5.00E-05,M
gBh-1m,,"Infection, herpes simplex virus remission/reduction, IN VITRO",Viral entry assay,IC-50,6.00E-05,M
Rifampicin,Enoyl-(Acyl-Carrier Protein) Reductase FabI (Bacterial) Inhibitors;RNA Polymerase (Bacterial) Inhibitors;Cell Wall Biosynthesis Inhibitors;Bacterial Fatty Acid Biosynthesis Inhibitors ,"Tuberculosis remission/reduction, IN VITRO",Broth dilution,MIC,6.00E-05,g/l
Indinavir sulfate,HIV Protease Inhibitors,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,7.02E-05,M
Bisaramil hydrochloride,,"Bradycardia induction, IN VIVO",,ED-15,7.40E-05,g
Levofloxacin,DNA Gyrase (Mycobacterium tuberculosis) Inhibitors;DNA Topoisomerase IV (Bacterial) Inhibitors,"Tuberculosis remission/reduction, IN VITRO",Dye assay (alamar blue),MIC,7.80E-05,g/l
Alizarin,DNA Methyltransferase 1 (DNMT1) Inhibitors,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Poly(dC)-poly(rG) as template primer,IC-50,1.00E-04,M
Bisphenol A,Transforming Growth Factor beta-1 Inhibitors;Fatty Acid Amide Hydrolase (FAAH) Inhibitors;TNF-alpha Modulators;IL-6 Modulators;Signal Transduction Modulators;Voltage-Dependent T-Type Calcium Channel Subunit alpha-1H (Cav3.2) Blockers,"Calcium-Activated Potassium Channel subunit alpha-1 (KCa1.1) activation, IN VITRO",Whole-cell patch-clamp assay (-80 mV),MEC,1.00E-04,M
Coronarin A,Angiogenesis Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",ELISA assay,IC-50,1.00E-04,M
Eremomycin,,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.00E-04,M
Etoricoxib,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-04,M
Ferulic acid,Antioxidants,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",Voltage-clamp assay,MIC,1.00E-04,M
Homocysteine,,Not Applicable,,MIC,1.00E-04,M
Lumiracoxib,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-04,M
Parecoxib sodium,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-04,M
Piroxicam,Signal Transduction Modulators;Cyclooxygenase (COX) Inhibitors,"Arthritis protection, IN VIVO",,ED-50,1.00E-04,g/kg
Rofecoxib,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-04,M
Valdecoxib,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators,"cGMP-Specific 3',5'-cyclic Phosphodiesterase (PDE5) inhibition, IN VITRO",Chemiluminescent assay,IC-50,1.00E-04,M
Vancomycin hydrochloride,Penicillin-Binding Protein (PBP) (Bacterial) Inhibitors;Cell Wall Biosynthesis Inhibitors,"Infection, viral remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.00E-04,M
Vanillin,Antioxidants,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,1.00E-04,M
Colistin sulfate,,"Infection, bacterial Gram-negative remission/reduction, IN VITRO",Broth dilution,MIC,1.25E-04,g/l
FG-2216,Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors;alpha-Ketoglutarate-Dependent Dioxygenase FTO Inhibitors,"Angiogenic Factor (nonspecified subtype) induction, IN VITRO",Matrigel-coated plate assay,MEC,1.25E-04,M
H2O2,,"Neurotoxicity induction, IN VITRO",Dye assay (MTT),EC-50,1.30E-04,M
NG-nitro-arginine,Signal Transduction Modulators;Nitric Oxide Synthase Inhibitors,"Inflammatory disorders remission/reduction, IN VITRO",,IC-50,1.49E-04,M
Stigmasterol,Antiinflammatory Drugs;Antioxidants,"Ribonuclease H (nonspecified subtype) inhibition, IN VITRO",Fluorescent assay,IC-50,1.58E-04,M
Triflocin,Mucin Production Inhibitors;Chloride Channel Protein 1 (CLCN1; ClC-1) Channel Blockers,"Calcium-Activated Chloride Channel Regulators (nonspecified subtype) blockade, IN VITRO",Whole-cell voltage-clamp assay (-50 mV),IC-50,1.59E-04,M
Abietic acid,11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors,"Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO",Fluorescent assay,IC-50,1.89E-04,M
Phloroglucinol,,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,2.00E-04,M
Zanamivir,Neuraminidase (Sialidase) (Influenza Virus) Inhibitors,"Ischemia, myocardia remission/reduction, IN VIVO",Infarct size,MED,2.00E-04,g/kg
Arachidonic acid,Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP4F2 Inhibitors,"Fibulin 2 inhibition, IN VITRO",RNA assay,MIC,2.50E-04,M
Ceftolozane sulfate/tazobactam,Cell Wall Biosynthesis Inhibitors;Penicillin-Binding Protein 3 (PBP3) (Pseudomonas aeruginosa) Inhibitors;Penicillin-Binding Protein 1b (PBP1b; mrcB) (Pseudomonas aeruginosa) Inhibitors;beta-Lactamase (Bacterial) Inhibitors,"Infection, Pseudomonas aeruginosa remission/reduction, IN VITRO",Broth dilution,MIC,2.50E-04,g/l
Terutroban sodium,Prostanoid TP Receptor Antagonists;Signal Transduction Modulators,"Thrombosis, arterial remission/reduction, IN VIVO",,ED-100,3.00E-04,g/kg
Ascorbic acid,Antioxidants;Aldose Reductase Inhibitors,"Oxidative stress remission/reduction, IN VITRO",Spectrophotometric assay,EC-50,3.30E-04,M
Xuefu Zhuyu,Angiogenesis Inducers,"Coronary heart disease remission/reduction, IN VIVO",,MED,3.40E-04,g/kg
Ibuprofen,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Acid-Sensing Ion Channels 1 (ASIC1) Blockers;Signal Transduction Modulators;NF-kappaB (NFKB) Activation Inhibitors;Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors,"Cytotoxicity induction, IN VITRO",Wound closure assay,IC-50,4.10E-04,M
Ethambutol,Cell Wall Biosynthesis Inhibitors,"Infection, mycobacterial remission/reduction, IN VITRO",Broth dilution,MIC,5.00E-04,g/l
JPL-32,,"Infection, HIV protection, IN VITRO",Dye assay,IC-50,6.30E-04,g/l
Ceftazidime/avibactam sodium,Penicillin-Binding Protein (PBP) (Bacterial) Inhibitors;Cell Wall Biosynthesis Inhibitors;beta-Lactamase (Bacterial) Inhibitors,"Infection, Pseudomonas aeruginosa remission/reduction, IN VITRO",Broth dilution,MIC,1.00E-03,g/l
Mucroporin,Cell Membrane Disrupting Agents,"Influenza A remission/reduction, IN VITRO",Plaque assay,IC-50,1.00E-03,g/l
RLip-aminoethylphosphonic acid,,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,1.00E-03,g/kg
Streptomycin,16S Ribosomal Protein Inhibitors;30S Ribosomal Protein Inhibitors,"Tuberculosis remission/reduction, IN VITRO",Broth dilution,MIC,1.00E-03,g/l
TG-6,Na+/H+ Exchanger type 1 (NHE-1) Inhibitors,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,1.00E-03,g/kg
Tigecycline dihydrochloride,30S Ribosomal Protein Inhibitors,"Infection, bacterial Gram-negative remission/reduction, IN VITRO",Broth dilution (calcium/magnesium-rich),MIC,1.00E-03,g/l
Salidroside,alpha-Synuclein (ASYN; NACP) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants;Antiamyloidogenic Agents,"AMP-activated Protein Kinase (AMPK) induction, EX VIVO",Chemiluminescent assay,MED,1.20E-03,g/l
Coronalolide methyl ester,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Leukemia, lymphocytic remission/reduction, IN VITRO",,CC-50,1.50E-03,g/l
Coronalolide,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Leukemia, lymphocytic remission/reduction, IN VITRO",,CC-50,1.73E-03,g/l
Pyrimethamine,Immune Checkpoint Inhibitors;Dihydrofolate Reductase (DHFR) (Protozoal) Inhibitors;Pharmacological Chaperones;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators;Anti-PD-1,"Leishmaniasis remission/reduction, IN VITRO",Dye assay (alamar blue),IC-30,1.78E-03,g/l
MK-626,Signal Transduction Modulators;Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,2.00E-03,g/kg
Trimetazidine,3-Ketoacyl-CoA Thiolase (3-KAT) Inhibitors,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,3.00E-03,g/kg
Pseudogensenoside G1,Platelet Adhesion Inhibitors,Not Applicable,Artery (coronary) ligation,MED,4.50E-03,g/kg
CMX-2043,,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,5.00E-03,g/kg
Oseltamivir phosphate,Neuraminidase (Sialidase) (Influenza Virus) Inhibitors,"Ischemia, myocardia remission/reduction, IN VIVO",ELISA assay,MED,5.00E-03,g/kg
Resveratrol-O-3'-glucoside,VCAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors;ICAM1 Expression Inhibitors,"Myocardial infarction protection, IN VIVO",Artery (coronary) ligation,MED,5.00E-03,g/kg
Oleic acid,Signal Transduction Modulators;PPARalpha Agonists,Not Applicable,,IC-50,6.17E-03,g/l
Gabapentin,Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands,"Pain, neuropathic remission/reduction, IN VIVO",Von Frey fiber assay,ED-50,9.20E-03,g/kg
Oleracein E,Antioxidants;Apoptosis Inhibitors;Free Radical Scavengers,"Coronary heart disease remission/reduction, IN VIVO",,MED,1.00E-02,g/kg
Tramadol hydrochloride,Signal Transduction Modulators;Norepinephrine Reuptake Inhibitors;5-HT Reuptake Inhibitors;mu-Opioid Receptor Agonists,"Pain, neuropathic remission/reduction, IN VIVO",Acetone withdrawal test,ED-50,1.03E-02,g/kg
Lamivudine/Zidovudine,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,1.25E-02,g/l
Meropenem,Penicillin-Binding Protein (PBP) (Bacterial) Inhibitors;Cell Wall Biosynthesis Inhibitors,"Pneumonia, bacterial remission/reduction, IN VITRO",,MIC,1.60E-02,g/l
Valsartan,Type-1 Angiotensin II Receptor (AGTR1; AT1) Antagonists;Signal Transduction Modulators,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,1.60E-02,g/kg/d
20(S)-Protopanaxadiol,Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators;Norepinephrine Reuptake Inhibitors;5-HT Reuptake Inhibitors;Apoptosis Inducers,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,2.50E-02,g/kg
Aliskiren hemifumarate,Renin Inhibitors,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,2.50E-02,g/kg/d
Carvacrol,Quorum Sensing Signaling Inhibitors;Antioxidants,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,2.50E-02,g/kg
Caulophine,,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,2.50E-02,g/kg
Human leukocyte interferon alpha,,"Cytotoxicity induction, IN VITRO",,CC-50,3.20E-02,M
Imipenem,Penicillin-Binding Protein (PBP) (Bacterial) Inhibitors;Cell Wall Biosynthesis Inhibitors,"Infection, bacterial Gram-negative remission/reduction, IN VITRO",Broth dilution (calcium/magnesium-rich),MIC,3.20E-02,g/l
Oleanolic acid 3-O-glucuronide,Glucose Lowering Agents,"Arrhythmia, ventricular remission/reduction, IN VIVO",Artery (coronary) ligation,MED,4.00E-02,g/kg
Scutellarein 7-O-glucuronide,Urease (Helicobacter pylori) Inhibitors;Antioxidants;Free Radical Scavengers,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,4.50E-02,g/kg
Lopinavir/ritonavir,HIV-1 Protease Inhibitors;HIV Protease Inhibitors;Tumor Necrosis Factor Receptor Superfamily Member 6 (CD95)/PLC-gamma-1 Interaction Inhibitors,"Cytotoxicity induction, IN VITRO",Dye assay (MTT),CC-50,4.70E-02,g/l
Acetylcysteine,NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Antioxidants,"Ischemia, myocardia protection, IN VIVO",Artery (coronary) ligation,MED,5.00E-02,g/kg
Ertapenem sodium,Penicillin-Binding Protein 2 (PBP2) (Escherichia coli) Inhibitors;Cell Wall Biosynthesis Inhibitors;beta-Lactamase (Bacterial) Inhibitors,"Infection, bacterial Gram-negative remission/reduction, IN VITRO",Broth dilution (calcium/magnesium-rich),MIC,6.40E-02,g/l
alpha-Hydroxyhydrocaffeic acid,VEGFR Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,6.87E-02,g/l
Salvianolic acid B,beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antiamyloidogenic Agents,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,1.42E-01,g/l
Dan-Lou,,"Coronary heart disease remission/reduction, IN VIVO",,MED,2.50E-01,g/kg
Daptomycin,Drugs Acting on Potassium Channels,"Infection, bacterial Gram-negative remission/reduction, IN VITRO",Broth dilution (calcium/magnesium-rich),MIC,2.56E-01,g/l
EtOH,,Not Applicable,,MEC,8.00E-01,g/l
Tanshinone,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,IC-50,8.42E-01,g/l
Dobutamine hydrochloride,Signal Transduction Modulators;beta1-Adrenoceptor Agonists,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,pIC-50,3.00E+00, 
Raloxifene hydrochloride,Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators;ENG Expression Enhancers;ACVRL1 Expression Enhancers,"L-Type Calcium Channel (nonspecified subtype) blockade, IN VITRO",Calcium-free medium,pIC-50,3.29E+00, 
Isradipine,Calcium Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,pIC-50,3.71E+00, 
Bay-k-8644,Transmembrane Protein 176B (TMEM176B) Inhibitors;L-Type Calcium Channel Activators,"L-Type Calcium Channel (nonspecified subtype) blockade, IN VITRO",Calcium-free medium,pIC-50,3.77E+00, 
Enoximone,Signal Transduction Modulators;Phosphodiesterase PDE3 Inhibitors,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,pIC-50,3.98E+00, 
Estradiol,,"Endothelin Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,4.48E+00, 
Telcagepant,Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,4.50E+00, 
Ibogaine,Serotonin Transporter (SERT) Ligands;Dopamine Transporter (DAT) Ligands;Signal Transduction Modulators;kappa-Opioid Receptor Ligands;mu-Opioid Receptor Ligands,"Muscarinic Acetylcholine Receptor (mAChR) (nonspecified subtype) affinity, IN VITRO",Displacement of [3H]-quinuclidinylbenzylate (QNB),pKi,4.63E+00, 
Sarpogrelate hydrochloride,5-HT2A Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 2A (5-HT2A) antagonism, IN VITRO",,pIC-50,4.79E+00, 
CVT-3032,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Adenosine A2A Receptor affinity, IN VITRO",Displacement of [3H]-ZM-241385,pKi,4.87E+00, 
Flupirtine maleate,NMDA Receptor Antagonists;Signal Transduction Modulators;Voltage-Gated K(V) 7 (KCNQ) Channel Activators,Not Applicable,,pEC-30,5.13E+00, 
Capsaicin,TRPV1 (Vanilloid VR1 Receptor) Agonists;Tumor NADH Oxidase (tNOX) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Quinolone resistance protein NorA (Staphylococcus aureus) Inhibitors,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,pIC-50,5.20E+00, 
L-Arginine hydrochloride,,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,pIC-50,5.22E+00, 
GMC-2021,5-HT1D Receptor Agonists;Signal Transduction Modulators,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,pIC-50,5.45E+00, 
R-phenylisopropyladenosine,Signal Transduction Modulators;Adenosine A1 Receptor Agonists,"Adenosine A2A Receptor affinity, IN VITRO",Displacement of [3H]-CPX,pKi,5.48E+00, 
Retigabine,Voltage-Gated K(V) 7.2/7.3 (KCNQ2/3) Channel Activators;Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Voltage-Gated K(V) 7.3 (KCNQ3) Channel Activators;GABA Aminotransferase Inhibitors,Not Applicable,,pEC-30,5.51E+00, 
N6-Cyclopentyladenosine,Signal Transduction Modulators;Adenosine A1 Receptor Agonists,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,pIC-50,5.63E+00, 
AM-630,Cannabinoid CB1 Receptor Inverse Agonists;Signal Transduction Modulators;Cannabinoid CB2 Receptor Antagonists;Cannabinoid CB2 Receptor Inverse Agonists,"Cannabinoid Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,5.72E+00, 
Sirolimus,CCR5 Expression Inhibitors;Signal Transduction Modulators;Proteasome Inhibitors;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Drugs Targeting B-Lymphocyte Antigen CD19,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,pA-2,5.74E+00, 
Piclidenoson,Signal Transduction Modulators;Adenosine A3 Receptor Agonists,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,pIC-50,5.93E+00, 
Calcimycin,,"alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO",,pIC-50,6.03E+00, 
CVT-2995,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Adenosine A1 Receptor affinity, IN VITRO",Displacement of [3H]-CPX,pKi,6.07E+00, 
Sumatriptan succinate,5-HT1D Receptor Agonists;5-HT1B Receptor Agonists;Solute Carrier Family 22 Member 3 (SLC22A3; OCT3) Inhibitors;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,6.18E+00, 
Acetylcholine chloride,Signal Transduction Modulators;Prostanoid EP1 Receptor Agonists;Muscarinic M1 Receptor Antagonists;Muscarinic M1 Receptor Agonists,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pIC-50,6.20E+00, 
Phenylephrine hydrochloride,alpha1A-Adrenoceptor Ligands;Histamine H1 Receptor Antagonists;Signal Transduction Modulators;alpha1-Adrenoceptor Agonists,"alpha-1 Adrenergic Receptors (nonspecified subtype) agonism, IN VITRO",,pEC-50,6.20E+00, 
Cyproheptadine hydrochloride,Histamine H1 Receptor Antagonists;5-HT2B Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 2A (5-HT2A) antagonism, IN VITRO",,pIC-50,6.27E+00, 
CGP-48369,Type-1 Angiotensin II Receptor (AGTR1; AT1) Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pIC-50,6.50E+00, 
Sufentanil citrate,Drugs Acting on Opioid and Opioid-Like Receptors;Signal Transduction Modulators,Not Applicable,,pEC-50,6.57E+00, 
Benazepril hydrochloride,Angiotensin-I Converting Enzyme (ACE) Inhibitors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pIC-50,6.60E+00, 
Calcitonin gene related peptide,Signal Transduction Modulators;Calcitonin Gene-Related Peptides (CGRP) Receptor Ligands,"Prostaglandin F2-alpha Receptor (PGF2-alpha Receptor) antagonism, IN VITRO",,pIC-50,6.70E+00, 
Linsidomine,Nitric Oxide (NO) Donors,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pIC-50,6.70E+00, 
DAGO,Signal Transduction Modulators;mu-Opioid Receptor Agonists,"delta-Type Opioid Receptor (DOP) agonism, IN VITRO",,pIC-50,6.71E+00, 
Sphingosine 1-phosphate,Sphingosine 1-Phosphate Receptor 1 (S1PR1; EDG1) Ligands;Signal Transduction Modulators;Apoptosis Inhibitors,Not Applicable,,pEC-50,6.71E+00, 
Probenecid,Multidrug Resistance-Associated Protein 1 (MRP-1; ABCC1) Inhibitors;TRPV2 (Vanilloid VR2 Receptor) Agonists,Not Applicable,,pIC-50,6.87E+00, 
Apelin,Signal Transduction Modulators;RAC Serine/Threonine-Protein Kinase (AKT; PKB) Activators;Apelin Receptor (Angiotensin Receptor-Like 1; APJ) Agonists;Phosphatidylinositol 3-Kinase (PI3K) Activators,Not Applicable,,pA-2,6.90E+00, 
Benazeprilat,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pIC-50,6.90E+00, 
Ritanserin,5-HT2A Receptor Antagonists;Signal Transduction Modulators;Diacylglycerol Kinase alpha (DGKA) Inhibitors,"5-Hydroxytryptamine Receptor 2A (5-HT2A) antagonism, IN VITRO",,pIC-50,6.99E+00, 
Ticagrelor,Signal Transduction Modulators;P2Y12 (P2T) Receptor Antagonists,"Equilibrative Nucleoside Transporter (ENT) (nonspecified subtype) inhibition, IN VITRO",,pIC-50,7.00E+00, 
W-146,Signal Transduction Modulators;Sphingosine 1-Phosphate Receptor 1 (S1PR1; EDG1) Antagonists,"Cannabinoid Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.04E+00, 
Mefloquine hydrochloride,Gap Junction delta-2 Protein (GJD2; Cx36) Blockers;Gap Junction alpha-8 Protein (GJA8; Cx50) Blockers;Signal Transduction Modulators;Pannexin-1 (PANX1; MRS1) Inhibitors;Adenosine A2A Receptor Antagonists,Not Applicable,,pIC-50,7.05E+00, 
Carbenoxolone sodium,11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors,Not Applicable,,pIC-50,7.12E+00, 
VPC-23019,Sphingosine 1-Phosphate Receptor 4 (S1PR4; EDG6) Agonists;Signal Transduction Modulators;Sphingosine 1-Phosphate Receptor 3 (S1PR3; EDG3) Antagonists;Sphingosine 1-Phosphate Receptor 1 (S1PR1; EDG1) Antagonists;Sphingosine 1-Phosphate Receptor 5 (S1PR5; EDG8) Partial Agonists,"Cannabinoid Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.18E+00, 
JTE-907,Signal Transduction Modulators;Cannabinoid CB2 Receptor Inverse Agonists,"Lysophospholipid (edg) Receptors (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.19E+00, 
Forskolin,Adenylate Cyclase Activators,Not Applicable,,pEC-30,7.24E+00, 
alphaCGRP(8-37),Signal Transduction Modulators;Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists,"Calcitonin Gene-Related Peptide Type 1 Receptor antagonism, IN VITRO",,pA-2,7.30E+00, 
Noradrenaline,alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists;Signal Transduction Modulators,"alpha-1 Adrenergic Receptors (nonspecified subtype) agonism, IN VITRO",,pEC-50,7.33E+00, 
RO-1138452,Signal Transduction Modulators;Prostanoid IP Receptor Antagonists,"Cannabinoid Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.33E+00, 
XAC,Signal Transduction Modulators;Adenosine A2B Receptor Antagonists,"Adenosine Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.37E+00, 
Frovatriptan,5-HT1B Receptor Agonists;5-HT1D Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,7.38E+00, 
HU-210,Signal Transduction Modulators;Cannabinoid CB2 Receptor Agonists;Cannabinoid CB1 Receptor Agonists,Not Applicable,,pEC-50,7.40E+00, 
Przewaquinone A,,"Prostanoid TP Receptor (Thromboxane A2 receptor; TXA2-R) (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.40E+00, 
CGS-15943,Signal Transduction Modulators;Adenosine Receptor Antagonists,"Adenosine A2A Receptor antagonism, IN VITRO",,pIC-50,7.45E+00, 
JTE-013,Signal Transduction Modulators;Sphingosine 1-Phosphate Receptor 2 (S1PR2; EDG5) Antagonists,"Lysophospholipid (edg) Receptors (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.62E+00, 
4'-I-SR-141716A,Signal Transduction Modulators;Cannabinoid CB1 Receptor Inverse Agonists;ACAT Inhibitors,"Cannabinoid Receptor (nonspecified subtype) antagonism, IN VITRO",,pIC-50,7.73E+00, 
BMS-181885,5-HT1D Receptor Agonists;Signal Transduction Modulators;5-HT1D Receptor Antagonists,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,7.90E+00, 
Endothelin 1,,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,7.96E+00, 
GR-125743,Signal Transduction Modulators;5-HT1D Receptor Antagonists,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pKb,8.00E+00, 
2HE-NECA,Signal Transduction Modulators;Adenosine A2A Receptor Agonists,"Adenosine A2A Receptor affinity, IN VITRO",Displacement of [3H]-ZM-241385,pKi,8.10E+00, 
Donitriptan hydrochloride,5-HT1B Receptor Agonists;5-HT1D Receptor Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 1D (5-HT1D) agonism, IN VITRO",,pEC-50,8.25E+00, 
Tegaserod maleate,5-HT4 Receptor Partial Agonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor (5-HT4) affinity, IN VITRO",Radioactivity assay,pKi,8.40E+00, 
AT-1015,5-HT2A Receptor Antagonists;Signal Transduction Modulators,"5-Hydroxytryptamine Receptor 2 (5-HT2) (nonspecified subtype) antagonism, IN VITRO",,pKb,8.61E+00, 
dl-Hyoscyamine,,"mu-Opioid (MOP) Receptor agonism, IN VITRO",,pIC-50,8.61E+00, 
Ketanserin,Signal Transduction Modulators;5-HT2 Receptor Antagonists,"5-Hydroxytryptamine Receptor 1D (5-HT1D) antagonism, IN VITRO",,pKb,8.70E+00, 
Serelaxin,Signal Transduction Modulators;Drugs Acting on Relaxin Receptors,Not Applicable,"Endothelial cells (coronary artery), human",pEC-50,9.30E+00, 
Brimonidine,,"delta-Type Opioid Receptor (DOP) agonism, IN VITRO",,pIC-50,9.49E+00, 
Olcegepant,Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists;Signal Transduction Modulators,"Calcitonin Gene-Related Peptide Type 1 Receptor antagonism, IN VITRO",,pA-2,1.01E+01, 
ODQ,Soluble Guanylyl Cyclase (sGC) Inhibitors;Potassium Channel Blockers,"K(ATP) Channel (nonspecified subtype) blockade, IN VITRO",,pIC-50,2.50E+01, 